News
-
-
-
PRESS RELEASE
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
Abivax presents four abstracts on obefazimod for ulcerative colitis and colon cancer model at Digestive Disease Week 2024. The company highlights novel mechanism of action and positive clinical data for obefazimod -
PRESS RELEASE
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024. The event will showcase new data on obefazimod's impact and mechanism of action -
-
PRESS RELEASE
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
Abivax informs shareholders of its ordinary and extraordinary general meeting on May 30, 2024, providing access to preparatory documents and details on participation. Obefazimod and Abivax information included -
PRESS RELEASE
Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
Abivax announces its annual ordinary and extraordinary general meeting on May 30, 2024, with preparatory documents available for shareholders. The meeting details, including agenda and resolutions, are accessible on the company's website -
-
-
-
Southern Energy Corp. Announces Payment of Interest in-Kind to its 8% Convertible Unsecured Subordinated Debentures
-
APWG 2024 Cybercrime Research Conference Extends Submission Deadline to July 7
-
Product Creation Studio Partners With PatchClamp Medtech Inc. to Develop Revolutionary Dural Repair System
-
XS Financial Enters Into Definitive Agreement to Be Taken Private
-
TRU Engages Investor Relations Specialists HE Capital Markets
-
DEFENCE’S ARM-X ANTI-CANCER VACCINE INHIBITS GROWTH OF PRE-ESTABLISHED OVARIAN CANCER RESULTING IN COMPLETE RESPONSES IN TREATED ANIMALS
-
Agreement reached with iBusiness Funding to acquire Funding Circle’s US business
-
Cairn Homes Plc: Transaction in Own Shares
-
Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
-
HORNBACH Group delivers strong Q1 2024/25 results increasing earnings per share y-o-y by 44% – full-year outlook confirmed unchanged
-
Signing of the share purchase agreement for the acquisition of a majority stake in Neoen by Brookfield from Impala and other shareholders and of a tender agreement between Brookfield and Bpifrance
-
Schneider Electric launches an offering of bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2031 for a nominal amount of €750 million and a concurrent repurchase of its outstanding OCEANEs due 2026
-
Gimv increases its stake in TINC – Gimv and Belfius conclude agreement in principle on the sale of the shares of Belfius Insurance in TINC
-
Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2024
-
2023/2024 Third Quarter Sales